StreetInsider.com News Articles

Bavarian Nordic wins DKK 700 million smallpox/mpox vaccine contract

Tue, 09 Jun 2026 06:50:09 -0400

Bavarian Nordic A/S (OMX: BAVA) announced it received a government contract valued over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine to an undisclosed country in 2026 and 2027.

The Danish vaccine company said deliveries under the contract will begin in 2026, with the majority of revenue recognized in 2027. The contract increases Bavarian Nordic's secured Public Preparedness business contracts for 2026 to approximately DKK 2.2 billion, up DKK 200 million from previously announced levels.

The company maintained its 2026 revenue guidance for Public Preparedness at DKK 2.3 billion to DKK 2.5 billion. Overall guidance for 2026 remains unchanged at revenue

Bavarian Nordic wins DKK 700 million smallpox/mpox vaccine contract

Tue, 09 Jun 2026 06:50:09 -0400

Bavarian Nordic A/S (OMX: BAVA) announced it received a government contract valued over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine to an undisclosed country in 2026 and 2027.

The company maintained its 2026 revenue guidance for Public Preparedness at DKK 2.3 billion to DKK 2.5 billion. Overall guidance for 2026 remains unchanged at revenue

Bavarian Nordic wins DKK 700 million smallpox/mpox vaccine contract

Tue, 09 Jun 2026 06:50:09 -0400

Bavarian Nordic A/S (OMX: BAVA) announced it received a government contract valued over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine to an undisclosed country in 2026 and 2027.

The company maintained its 2026 revenue guidance for Public Preparedness at DKK 2.3 billion to DKK 2.5 billion. Overall guidance for 2026 remains unchanged at revenue

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed country in 2026 and 2027.

Paul Chaplin, President & CEO of Bavarian Nordic, said: “We are pleased to expand our commitment to supporting governments in their efforts to protect populations against mpox and smallpox. MVA-BN remains a critical tool for both outbreak response and long-term stockpiling. Ensuring reliable access to medical countermeasures requires sustained investment in preparedness, strategic stockpiles and manufacturing capabilities that can

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Tue, 09 Jun 2026 06:49:00 -0400

Bavarian Nordic A/S (BAVA:CN) (BVNRY) PT Raised to DKK280 at Jefferies

Wed, 20 May 2026 01:00:41 -0400

Jefferies analyst Peter Welford raised the price target on Bavarian Nordic A/S (BAVA:CN) (OTC: BVNRY) to DKK280.00 (from DKK275.00) while maintaining a Buy rating.

Bavarian Nordic A/S (BAVA:CN) (BVNRY) PT Raised to DKK280 at Jefferies

Wed, 20 May 2026 01:00:41 -0400

Jefferies analyst Peter Welford raised the price target on Bavarian Nordic A/S (BAVA:CN) (OTC: BVNRY) to DKK280.00 (from DKK275.00) while maintaining a Buy rating.

Bavarian Nordic A/S (BAVA:CN) (BVNRY) PT Raised to DKK280 at Jefferies

Wed, 20 May 2026 01:00:41 -0400

Jefferies analyst Peter Welford raised the price target on Bavarian Nordic A/S (BAVA:CN) (OTC: BVNRY) to DKK280.00 (from DKK275.00) while maintaining a Buy rating.

Bavarian Nordic A/S (BAVA:CN) (BVNRY) PT Raised to DKK280 at Jefferies

Wed, 20 May 2026 01:00:41 -0400

Jefferies analyst Peter Welford raised the price target on Bavarian Nordic A/S (BAVA:CN) (OTC: BVNRY) to DKK280.00 (from DKK275.00) while maintaining a Buy rating.

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic

Mon, 28 Jul 2025 02:08:00 -0400